Diane Stephenson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Diane Stephenson has a total of 294 co-authors. Here are the top co-authors by number of shared publications:
Klaus Romero
Critical Path for Parkinson's Consortium, Critical Path Institute, Tucson, AZ, USA
9 shared publicationsMark Forrest Gordon
CPP Scientific Advisor, PA, USA
4 shared publications- Martijn L. T. M. Muller
Critical Path Institute, Tucson, AZ, United States
4 shared publications Brian Corrigan
Division of Pharmacometrics, Pfizer Global Research and Development, Groton, CT, USA
3 shared publications- Cheryl D. Coon
Clinical Outcome Assessment Program, Critical Path Institute, Tucson, USA
3 shared publications Ken Marek
Institute of Neurodegenerative Diseases, New Haven, Connecticut, USA
3 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
Reciprocity in research: Participant views on return of results in the WATCH-PD qualitative study
Background: Research participants increasingly desire access to their personalized results. A growing emphasis on patient engagement and recognition of participants as partners in research has intensified ethical considerations around data sharing and return of results. While some research teams have started returning personalized results, important questions remain about how to do so responsibly and effectively. Objective: To explore the perspectives of people with Parkinson's on return of individual research results, including preferences regarding digital data. Methods: This qualitative sub-study was conducted as part the WATCH-PD study (Wearable Assessments in The Clinic and at Home in PD). Online qualitative interviews to explore perceptions on return of research results were conducted annually each year from 2022–2025. Content analysis techniques were used to analyze transcripts. Results: 33 participants completed interviews and were included in the analysis. Three themes emerged: (1) Most participants desire to receive personal results provided the results are understandable to them; (2) Knowing personal results could support disease management and future planning; and (3) Access to data is an ethical obligation of the research team and a reciprocal return of personal information. Conclusions: Participants in this study wanted the choice to receive personal research results, and most preferred disclosure even when findings might be unfavorable. Although returning person-level data presents logistical and ethical challenges, engaging participants as partners through transparent data sharing may strengthen engagement, trust, and advance patient-centered research.
- 30 September 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
Open AccessReciprocity in research: Participant views on return of results in the WATCH-PD qualitative study
Background: Research participants increasingly desire access to their personalized results. A growing emphasis on patient engagement and recognition of participants as partners in research has intensified ethical considerations around data sharing and return of results. While some research teams have started returning personalized results, important questions remain about how to do so responsibly and effectively. Objective: To explore the perspectives of people with Parkinson's on return of individual research results, including preferences regarding digital data. Methods: This qualitative sub-study was conducted as part the WATCH-PD study (Wearable Assessments in The Clinic and at Home in PD). Online qualitative interviews to explore perceptions on return of research results were conducted annually each year from 2022–2025. Content analysis techniques were used to analyze transcripts. Results: 33 participants completed interviews and were included in the analysis. Three themes emerged: (1) Most participants desire to receive personal results provided the results are understandable to them; (2) Knowing personal results could support disease management and future planning; and (3) Access to data is an ethical obligation of the research team and a reciprocal return of personal information. Conclusions: Participants in this study wanted the choice to receive personal research results, and most preferred disclosure even when findings might be unfavorable. Although returning person-level data presents logistical and ethical challenges, engaging participants as partners through transparent data sharing may strengthen engagement, trust, and advance patient-centered research.
- Open Access
- 30 September 2026
- Published by Henry Stewart Talks in The Biomedical & Life Sciences Collection
- Vol. 2026 (9) , e1006944
Digital health technologies (DHTs) for drug development in CNS diseases
Click to launch & play an online audio visual presentation by Dr. Diane T. Stephenson on Digital health technologies (DHTs) for drug development in CNS diseases, part of a collection of multimedia lectures.
- 30 September 2026
- Published by Henry Stewart Talks in The Biomedical & Life Sciences Collection
- Vol. 2026 (9) , e1006944
Open AccessDigital health technologies (DHTs) for drug development in CNS diseases
Click to launch & play an online audio visual presentation by Dr. Diane T. Stephenson on Digital health technologies (DHTs) for drug development in CNS diseases, part of a collection of multimedia lectures.
- Open Access
- 26 September 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
Psychometric evaluation of MDS-UPDRS Part I and II to support patient-focused drug development in early Parkinson’s clinical trials
Background: The MDS-UPDRS is the gold-standard clinical outcome assessment (COA) used in Parkinson’s disease (PD) clinical trials. Given the rich pipeline of therapeutics with a focus on earlier intervention, evaluation of the measure for an early PD target population is needed. The aim of this work is to better understand the psychometric/statistical support of the MDS-UPDRS items in an early PD population. Multiple-group latent variable models were used to examine the performance of the patient-reported outcome portions (Parts I and II) of the MDS-UPDRS. Methodology: Data from multiple studies, both observational and clinical trials, included in the Critical Path for Parkinson’s Integrated Database were pooled and used in the reported analyses. The latent variable analysis framework was used to explore the dimensionality of the noted parts of the MDS-UPDRS using multiple-group item factor analysis and item response theory models, with groups defined by Hoehn & Yahr (H&Y) stage. Specifically, multiple-group (H&Y Stages 1, 2, and 3) item factor analyses were used to explore the dimensionality of the examined MDS-UPDRS parts and, after achieving acceptable model, the final factor analysis model was reparameterized as a multiple-group item response theory model to provide a more detailed evaluation of the performance of the measure and the individual items contributing to the measure. Results: The unidimensionality of Part II was supported by latent variable modeling results. For Part I, a multidimensional model that included method factors for reporter (i.e., clinician-reported versus patient-reported items) provided good fit to the data. The scores from both examined parts of the MDS-UPDRS were found to have acceptable reliability for continued use in PD research. Conclusions: Based on the multiple-group analyses of Part II of the MDS-UPDRS, summed scores from these items may be supportable. In contrast, the best fitting model applied to Part I of the MDS-UPDRS suggests that summed scores may not be appropriate for summarizing these items, as accounting for reporter in scoring appears to be important. These results provide further guidance for the use of this tool in early PD for urgently needed disease-modifying treatments.
- 26 September 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
Open AccessPsychometric evaluation of MDS-UPDRS Part I and II to support patient-focused drug development in early Parkinson’s clinical trials
Background: The MDS-UPDRS is the gold-standard clinical outcome assessment (COA) used in Parkinson’s disease (PD) clinical trials. Given the rich pipeline of therapeutics with a focus on earlier intervention, evaluation of the measure for an early PD target population is needed. The aim of this work is to better understand the psychometric/statistical support of the MDS-UPDRS items in an early PD population. Multiple-group latent variable models were used to examine the performance of the patient-reported outcome portions (Parts I and II) of the MDS-UPDRS. Methodology: Data from multiple studies, both observational and clinical trials, included in the Critical Path for Parkinson’s Integrated Database were pooled and used in the reported analyses. The latent variable analysis framework was used to explore the dimensionality of the noted parts of the MDS-UPDRS using multiple-group item factor analysis and item response theory models, with groups defined by Hoehn & Yahr (H&Y) stage. Specifically, multiple-group (H&Y Stages 1, 2, and 3) item factor analyses were used to explore the dimensionality of the examined MDS-UPDRS parts and, after achieving acceptable model, the final factor analysis model was reparameterized as a multiple-group item response theory model to provide a more detailed evaluation of the performance of the measure and the individual items contributing to the measure. Results: The unidimensionality of Part II was supported by latent variable modeling results. For Part I, a multidimensional model that included method factors for reporter (i.e., clinician-reported versus patient-reported items) provided good fit to the data. The scores from both examined parts of the MDS-UPDRS were found to have acceptable reliability for continued use in PD research. Conclusions: Based on the multiple-group analyses of Part II of the MDS-UPDRS, summed scores from these items may be supportable. In contrast, the best fitting model applied to Part I of the MDS-UPDRS suggests that summed scores may not be appropriate for summarizing these items, as accounting for reporter in scoring appears to be important. These results provide further guidance for the use of this tool in early PD for urgently needed disease-modifying treatments.
- Open Access
- 24 July 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (6) , 1296-1312
Regulatory endorsement for the application of α-synuclein seed amplification assay as a susceptibility and risk biomarker for clinical trials targeting synucleinopathies
Transformation in the neurosciences in biomarkers is enabling novel therapeutic strategies targeting earlier stages of disease prior to onset of clinical symptoms. Emerging progress in the area of synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB) have significant implications for clinical trials. Misfolded α-synuclein aggregates (syn-seeds) propagate by templated misfolding of native α-synuclein, driving disease spread. The advent of the α-synuclein seed amplification assay (syn SAA) now enables highly sensitive and specific detection of syn-seeds in cerebrospinal fluid (CSF), allowing in vivo identification of underlying α-synuclein pathology, including in individuals prior to the onset of motor symptoms. To support regulatory alignment, the Critical Path Institute's Critical Path for Parkinson's (CPP) consortium compiled and evaluated the totality of scientific evidence in the area of syn SAA as an in vivo measure of misfolded alpha synuclein in CSF and submitted it to the U.S. Food and Drug Administration (FDA) in a request for a Biomarker Letter of Support (LoS). Within three months of submission, the FDA issued a LoS endorsing CSF syn SAA as a susceptibility and risk biomarker for use in clinical trials targeting α-synuclein–related neurodegenerative diseases, enabling enrichment of participants with underlying pathology and reducing trial risk. These data have enabled the development of biological classification frameworks for synucleinopathies that define disease based on molecular pathology rather than clinical symptoms alone. This review summarizes the regulatory-grade evidence supporting syn SAA and discusses its implications for biologically driven clinical trial design and early-intervention strategies.
- 24 July 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (6) , 1296-1312
Open AccessRegulatory endorsement for the application of α-synuclein seed amplification assay as a susceptibility and risk biomarker for clinical trials targeting synucleinopathies
Transformation in the neurosciences in biomarkers is enabling novel therapeutic strategies targeting earlier stages of disease prior to onset of clinical symptoms. Emerging progress in the area of synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB) have significant implications for clinical trials. Misfolded α-synuclein aggregates (syn-seeds) propagate by templated misfolding of native α-synuclein, driving disease spread. The advent of the α-synuclein seed amplification assay (syn SAA) now enables highly sensitive and specific detection of syn-seeds in cerebrospinal fluid (CSF), allowing in vivo identification of underlying α-synuclein pathology, including in individuals prior to the onset of motor symptoms. To support regulatory alignment, the Critical Path Institute's Critical Path for Parkinson's (CPP) consortium compiled and evaluated the totality of scientific evidence in the area of syn SAA as an in vivo measure of misfolded alpha synuclein in CSF and submitted it to the U.S. Food and Drug Administration (FDA) in a request for a Biomarker Letter of Support (LoS). Within three months of submission, the FDA issued a LoS endorsing CSF syn SAA as a susceptibility and risk biomarker for use in clinical trials targeting α-synuclein–related neurodegenerative diseases, enabling enrichment of participants with underlying pathology and reducing trial risk. These data have enabled the development of biological classification frameworks for synucleinopathies that define disease based on molecular pathology rather than clinical symptoms alone. This review summarizes the regulatory-grade evidence supporting syn SAA and discusses its implications for biologically driven clinical trial design and early-intervention strategies.
- Open Access
- 31 July 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27 (1) , e67052
Advancing the Integration of Digital Health Technologies in the Drug Development Ecosystem
Optimized frameworks for efficient and scalable deployment of digital health technologies (DHT) are needed to address existing bottlenecks and unlock the opportunities for remote monitoring and operationalizing decentralized trials. DHTs offer immense potential opportunities for transformation in drug development by providing remote, high frequency, longitudinal insights into physiological processes, and how participants feel and function. Currently, DHT-based drug development tool–related efforts have yielded valuable insights into effective practices and areas that need improvement. However, the development of the required infrastructure is a resource-intensive task, and its efficiency can be greatly enhanced by systematically identifying the required components and aligning them in ways that will avoid trial-and-error approaches by various stakeholders. In this perspective paper, we aim to highlight these crucial aspects required for supporting the rapid and large-scale deployment of DHTs. We propose the development of various standardized consensus frameworks to clearly lay out processes for various stakeholders and facilitate the seamless integration of the next generation of health care–sensing technologies into drug development.
- 31 July 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27 (1) , e67052
Open AccessAdvancing the Integration of Digital Health Technologies in the Drug Development Ecosystem
Optimized frameworks for efficient and scalable deployment of digital health technologies (DHT) are needed to address existing bottlenecks and unlock the opportunities for remote monitoring and operationalizing decentralized trials. DHTs offer immense potential opportunities for transformation in drug development by providing remote, high frequency, longitudinal insights into physiological processes, and how participants feel and function. Currently, DHT-based drug development tool–related efforts have yielded valuable insights into effective practices and areas that need improvement. However, the development of the required infrastructure is a resource-intensive task, and its efficiency can be greatly enhanced by systematically identifying the required components and aligning them in ways that will avoid trial-and-error approaches by various stakeholders. In this perspective paper, we aim to highlight these crucial aspects required for supporting the rapid and large-scale deployment of DHTs. We propose the development of various standardized consensus frameworks to clearly lay out processes for various stakeholders and facilitate the seamless integration of the next generation of health care–sensing technologies into drug development.
- Open Access
- 15 January 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (2) , 1-20
Longitudinal qualitative assessment of meaningful symptoms and relevance of WATCH-PD digital measures for people with early Parkinson’s
Background: Longitudinal qualitative data on what matters to people with Parkinson’s disease are lacking and needed to guide patient-centered clinical care and development of outcome measures. Objective: To evaluate change over time in symptoms, impacts, and relevance of digital measures to monitor disease progression in early Parkinson’s. Methods: In-depth, online symptom mapping interviews were conducted with 33 people with early Parkinson’s at baseline and 1 year later to evaluate (A) symptoms, (B) impacts, and (C) relevance of digital measures to monitor personally relevant symptoms. Maps and transcripts were coded for frequencies, Likert scale rankings (0 = not present to 4 = most bothersome), and thematic findings. Wilcoxon Signed Rank test was used to evaluate change over time. Results: Other than walking and balance, most motor symptoms did not change significantly from baseline to 1 year later. Multiple significant changes were observed in non-motor areas (cognition, speech, sleep, mood, fatigue, pain; p < 0.05) and functional impacts (mobility, effort to do usual activities, personal comfort; p < 0.05). Thematic analysis revealed ability to cope with and compensate for actual or anticipated symptoms reduced disruptions to well-being and changed how bothersome symptoms were. All digital measures targeted symptoms that were personally important to most participants (> 80%). Conclusion: Non-motor and walking/balance symptoms changed sooner than other motor symptoms during the course of 1 year. Evaluation of coping and compensatory mechanisms may be essential to understanding symptom bothersomeness at a given point in time. Smartphone and smartwatch digital measures were relevant to personally meaningful symptoms of early PD.
- 15 January 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (2) , 1-20
Open AccessLongitudinal qualitative assessment of meaningful symptoms and relevance of WATCH-PD digital measures for people with early Parkinson’s
Background: Longitudinal qualitative data on what matters to people with Parkinson’s disease are lacking and needed to guide patient-centered clinical care and development of outcome measures. Objective: To evaluate change over time in symptoms, impacts, and relevance of digital measures to monitor disease progression in early Parkinson’s. Methods: In-depth, online symptom mapping interviews were conducted with 33 people with early Parkinson’s at baseline and 1 year later to evaluate (A) symptoms, (B) impacts, and (C) relevance of digital measures to monitor personally relevant symptoms. Maps and transcripts were coded for frequencies, Likert scale rankings (0 = not present to 4 = most bothersome), and thematic findings. Wilcoxon Signed Rank test was used to evaluate change over time. Results: Other than walking and balance, most motor symptoms did not change significantly from baseline to 1 year later. Multiple significant changes were observed in non-motor areas (cognition, speech, sleep, mood, fatigue, pain; p < 0.05) and functional impacts (mobility, effort to do usual activities, personal comfort; p < 0.05). Thematic analysis revealed ability to cope with and compensate for actual or anticipated symptoms reduced disruptions to well-being and changed how bothersome symptoms were. All digital measures targeted symptoms that were personally important to most participants (> 80%). Conclusion: Non-motor and walking/balance symptoms changed sooner than other motor symptoms during the course of 1 year. Evaluation of coping and compensatory mechanisms may be essential to understanding symptom bothersomeness at a given point in time. Smartphone and smartwatch digital measures were relevant to personally meaningful symptoms of early PD.
- Open Access
- 14 January 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (1) , 227-235
Addressing the need for standardization of symptomatic medication documentation in Parkinson's disease clinical research: A call to action
People with Parkinson's disease (PD) are prescribed a variety of medications to mitigate symptoms and improve their quality of life. These symptomatic therapies cover a range of pharmacological classes, including classical dopaminergic treatments, other antiparkinsonian agents, and pharmacotherapies for non-PD conditions. Often, medications are prescribed for concomitant use and in increasing doses, particularly as the disease progresses. Documentation of these interventions in clinical trials is necessary to accurately capture medication usage, compare medication utilization across different studies, understand factors contributing to experimental therapeutic response, and analyze clinical trial data in a precise manner. At the present time, there is no current international standard for how these medications are documented within clinical trials. As a case example, we will highlight medication use documentation in a large international multicenter observational study commonly used as a reference for design of clinical trials. This review aims to raise awareness within the scientific community of the importance of proper medication documentation and the need for standardization to harmonize prescriptive practices, improve treatment interpretability, and perform consistently robust analyses from clinical trials data.
- 14 January 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (1) , 227-235
Open AccessAddressing the need for standardization of symptomatic medication documentation in Parkinson's disease clinical research: A call to action
People with Parkinson's disease (PD) are prescribed a variety of medications to mitigate symptoms and improve their quality of life. These symptomatic therapies cover a range of pharmacological classes, including classical dopaminergic treatments, other antiparkinsonian agents, and pharmacotherapies for non-PD conditions. Often, medications are prescribed for concomitant use and in increasing doses, particularly as the disease progresses. Documentation of these interventions in clinical trials is necessary to accurately capture medication usage, compare medication utilization across different studies, understand factors contributing to experimental therapeutic response, and analyze clinical trial data in a precise manner. At the present time, there is no current international standard for how these medications are documented within clinical trials. As a case example, we will highlight medication use documentation in a large international multicenter observational study commonly used as a reference for design of clinical trials. This review aims to raise awareness within the scientific community of the importance of proper medication documentation and the need for standardization to harmonize prescriptive practices, improve treatment interpretability, and perform consistently robust analyses from clinical trials data.
- Open Access
- 7 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Advancing the Integration of Digital Health Technologies in the Drug Development Ecosystem (Preprint)
UNSTRUCTURED Optimized frameworks for efficient and scalable deployment of digital health technologies (DHT) are needed to address existing bottlenecks and unlock the opportunities for remote monitoring and operationalizing decentralized trials. DHTs offer immense potential opportunities for transformation in drug development by providing remote, high frequency, longitudinal insights into physiological processes, and how participants feel and function. Currently, DHT-based drug development tool–related efforts have yielded valuable insights into effective practices and areas that need improvement. However, the development of the required infrastructure is a resource-intensive task, and its efficiency can be greatly enhanced by systematically identifying the required components and aligning them in ways that will avoid trial-and-error approaches by various stakeholders. In this perspective paper, we aim to highlight these crucial aspects required for supporting the rapid and large-scale deployment of DHTs. We propose the development of various standardized consensus frameworks to clearly lay out processes for various stakeholders and facilitate the seamless integration of the next generation of health care–sensing technologies into drug development.
- 7 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAdvancing the Integration of Digital Health Technologies in the Drug Development Ecosystem (Preprint)
UNSTRUCTURED Optimized frameworks for efficient and scalable deployment of digital health technologies (DHT) are needed to address existing bottlenecks and unlock the opportunities for remote monitoring and operationalizing decentralized trials. DHTs offer immense potential opportunities for transformation in drug development by providing remote, high frequency, longitudinal insights into physiological processes, and how participants feel and function. Currently, DHT-based drug development tool–related efforts have yielded valuable insights into effective practices and areas that need improvement. However, the development of the required infrastructure is a resource-intensive task, and its efficiency can be greatly enhanced by systematically identifying the required components and aligning them in ways that will avoid trial-and-error approaches by various stakeholders. In this perspective paper, we aim to highlight these crucial aspects required for supporting the rapid and large-scale deployment of DHTs. We propose the development of various standardized consensus frameworks to clearly lay out processes for various stakeholders and facilitate the seamless integration of the next generation of health care–sensing technologies into drug development.
- Open Access
- 16 November 2023
- Published by Elsevier in Neurotherapeutics
- Vol. 20 (6) , 1893
Correction: Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop
- 16 November 2023
- Published by Elsevier in Neurotherapeutics
- Vol. 20 (6) , 1893
Open AccessCorrection: Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop
- Open Access
- 12 October 2023
- Published by Elsevier in Neurotherapeutics
- Vol. 20 (6) , 1682-1691
Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop
- 12 October 2023
- Published by Elsevier in Neurotherapeutics
- Vol. 20 (6) , 1682-1691
Open AccessTransforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop